DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Update

DBV Technologies S.A. (NASDAQ:DBVT) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 298,500 shares, an increase of 7.1% from the August 31st total of 278,800 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 48,300 shares, the short-interest ratio is presently 6.2 days.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Trading Up 3.5 %

DBVT stock traded up $0.02 during midday trading on Monday, hitting $0.72. The stock had a trading volume of 52,076 shares, compared to its average volume of 51,919. The firm has a market cap of $69.47 million, a P/E ratio of -0.83 and a beta of 0.68. The business has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $1.06. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.74.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period last year, the business posted ($0.26) earnings per share. On average, equities analysts anticipate that DBV Technologies will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DBVT shares. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of DBV Technologies in a report on Thursday, August 1st. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th. Finally, StockNews.com began coverage on DBV Technologies in a report on Friday. They issued a “hold” rating on the stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.